Eptotermin alfa - Ember Therapeutics

Drug Profile

Eptotermin alfa - Ember Therapeutics

Alternative Names: 38A BMP-7 - Ember Therapeutics; Recombinant bone morphogenetic protein-7 - Ember Therapeutics; Recombinant osteogenetic protein-1 - Ember Therapeutics; rhBMP-7 - Ember Therapeutics; rhOP-1 - Ember Therapeutics

Latest Information Update: 03 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Stryker Corporation
  • Developer Ember Therapeutics
  • Class Bone morphogenetic proteins; Calcium regulators; Osteoporosis therapies; Recombinant proteins
  • Mechanism of Action Apoptosis inhibitors; Collagen stimulants; Osteogenesis stimulants; Proteoglycan stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Osteoarthritis
  • Preclinical Nephritis; Renal failure

Most Recent Events

  • 03 Apr 2017 Phase-II development for Osteoarthritis of knee is ongoing in USA (Intra-articular)
  • 06 Jul 2016 Eptotermin alfa licensed to Knight Therapeutics for marketing in Romania and the Caribbean
  • 19 Oct 2015 Eptotermin alfa - Ember Therapeutics is available for licensing as of 19 Oct 2015. http://www.embertx.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top